Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 NR2F1 expression and clinical outcome

From: NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

  Fraction of DTCs categorized as NR2F1high Distant metastasis (all) or death from breast cancer (%) Bone metastasisb (%)
All patientsa (n = 26) < 50% 0 to < 50% NR2F1high 17/19 (89.5) 10/15 (66.7)
0–1% NR2F1high 13/15 (86.7) 9/14 (64.3)
50–100% 4/7 (57.1) 2/7 (28.6)
Patients without metastasis prior to last DTC-positive BMA and no negative DTC status at subsequent BMA (n = 18) < 50% 0 to < 50% NR2F1high 13/14 (92.9) 9/12 (75.0)
0–1% NR2F1high 11/12 (91.7) 8/11 (72.7)
50–100% 1/4 (25.0) 1/4 (25.0)
Patients with no metastasis at time point for last DTC-positive BMA, no negative DTC status at subsequent BMA, and no chemotherapy after the BM analysis (n = 14) < 50% 0 to < 50% NR2F1high 11/12 (91.7) 7/10 (70.0)
0–1% NR2F1high 9/10 (90.0) 6/9 (66.7)
50–100% 1/2 (50.0) 1/2 (50.0)
  1. If analysis was performed at more than one time point, the last disseminated tumor cell (DTC)-positive sample is included
  2. BMA bone marrow aspirate
  3. aIncludes results from 4 patients with metastases detected before bone marrow (BM) analysis and 8 patients receiving chemotherapy after the BM analysis
  4. bNo information on bone metastasis status was available from four patients in total